{"cluster": 36, "subcluster": 41, "abstract_summ": "PAR1 activation also impacts on the actions of other cell types involved in COVID-19 pathobiology, including endothelial cells, fibroblasts and pulmonary alveolar epithelial cells.The evidence to date supports the concept that the thrombotic manifestations of severe COVID-19 is due to the ability of SARS-CoV-2 to invade endo\u00acthelial cells via angiotensin-converting enzyme 2 (ACE2), which is expressed on the endothelial cell surface.Upon infection or cell damage, high amounts of adenosine triphosphate (ATP) are released from damaged cells, which serve as mediators of inflammation through purinergic cell surface receptor signaling.Mice with pericyte ablation show increased expression and release of Von Willebrand Factor from microvascular endothelial cells, suggesting that pericytes orchestrate thrombogenic responses in neighboring endothelial cells.Indeed, the COVID-19 virus binds to angiotensin-converting enzyme type 2 (ACE2), which is expressed in endothelial cells.", "title_summ": "The Endothelial Dysfunction and Pyroptosis Driving the SARS-CoV-2 Immune-ThrombosisIncreased Expression of Chondroitin Sulfotransferases following AngII may Contribute to Pathophysiology Underlying Covid-19 Respiratory Failure: Impact may be Exacerbated by Decline in Arylsulfatase B ActivityPericyte-specific vascular expression of SARS-CoV-2 receptor ACE2 \u2013 implications for microvascular inflammation and hypercoagulopathy in COVID-19 patientsA Novel Method of Immunomodulation of Endothelial cells Using Streptococcus Pyogenes and its LysateNew Soluble Angiopoietin Analog of C4BP-ANG1 Prevents Pathological Vascular LeakagePotential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients?Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatmentThe vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infectionCan COVID 2019 disease induces a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidaseCan Bioactive Lipids Inactivate Coronavirus (COVID-19)?Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?\u201cWar to the knife\u201d against thromboinflammation to protect endothelial function of COVID-19 patientsCOVID-19 and heme oxygenase: novel insight into the disease and potential therapiesCOVID-19: hemoglobin, iron, and hypoxia beyond inflammation.Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?The synthetic LPS binding peptide 19-2.5 interferes with clotting and prevents degradation of high molecular weight kininogen in plasma.Potential role of endothelial cell surface ectopic redox complexes in COVID-19 disease pathogenesis.Ibudilast, a Phosphodiesterase-4 Inhibitor, Ameliorates Acute Respiratory Distress Syndrome in Neonatal Mice by Alleviating Inflammation and Apoptosis.Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak.", "title_abstract_phrases": "PAR1 activation also impacts on the actions of other cell types involved in COVID-19 pathobiology, including endothelial cells, fibroblasts and pulmonary alveolar epithelial cells.Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidaseThe high rate of thrombotic complications associated with COVID-19 seems likely to reflect viral infection of vascular endothelial cells, which express the ACE2 protein that enables SARS-CoV-2 to invade cells.The evidence to date supports the concept that the thrombotic manifestations of severe COVID-19 is due to the ability of SARS-CoV-2 to invade endo\u00acthelial cells via angiotensin-converting enzyme 2 (ACE2), which is expressed on the endothelial cell surface.Mice with pericyte ablation show increased expression and release of Von Willebrand Factor from microvascular endothelial cells, suggesting that pericytes orchestrate thrombogenic responses in neighboring endothelial cells.Our findings provide a novel and promising strategy to regulate pulmonary inflammation in ARDS.The Endothelial Dysfunction and Pyroptosis Driving the SARS-CoV-2 Immune-ThrombosisObjective: Endothelial activation after viral infection could contribute to changes in the vascular glycocalyx associated with programmed inflammatory cell death called pyroptosis."}